Trial Profile

A Phase II Study Comparing Salvage Radiotherapy in Combination With 6 Months of Androgen-deprivation Therapy Versus Anti-androgen Therapy With Apalutamide in Patients With Biochemical Progression After Radical Prostatectomy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Degarelix; Goserelin; Leuprorelin; Triptorelin
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms SAVE

06 Feb 2024 Planned End Date changed from 1 Sep 2022 to 1 Dec 2025.
06 Feb 2024 Planned primary completion date changed from 1 Dec 2021 to 1 Aug 2025.
03 Feb 2020 According to a Janssen media release, data from this trial will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com